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Purpose: To evaluate the level of matrix metalloproteinase (MMP)-2 and MMP-9 activities in patients with steroid induced
posterior subcapsular cataract (PSC).
Methods: This prospective, observational study comprised of 156 patients having either steroid induced PSC (n=50) or
non-steroidal PSC (n=106) were performed to evaluate the level of MMP-2 and MMP-9 activities in the lens epithelial
cells (LECs) and the serum. Anterior lens capsules harboring LECs were obtained during phacoemulsification and
peripheral blood was collected from patients before administration of anesthesia. Serum was separated by centrifugation
at 10,000× g for 15 min at 4 °C. The LECs and serum samples were processed to analyze MMP-2 and MMP-9 activities
using succinylated gelatin assay. Quantitative real time-PCR (qRT–PCR) was performed to determine the mRNA levels
of MMP-2 and MMP-9 in LECs. The mRNA levels were expressed as a ratio, using the delta-delta method for comparing
the relative expression results between cases with steroid induced PSC and cases with non-steroidal PSC. MMP-2 and
MMP-9 levels were also compared in the two groups using immunolocalization.
Results: The level of MMP-2 and MMP-9 activity was found to be high in LECs and serum of cases with steroid induced
PSC. Further in all steroid induced cases, a 1.4 fold increase was observed in MMP-2 activity in LECs and a 1.4 fold
increase in MMP-9 activity in the serum. Both qRT–PCR and immunolocalization showed increased expression of MMP-2
and MMP-9 activity.
Conclusions: MMP-2 and MMP-9 activity in both LECs and serum was significantly higher in cases with steroid induced
PSC. The possible use of MMP-9 as a non-invasive biomarker in ascertaining the presence of steroid induced PSC should
be evaluated using a larger sample size.
Posterior subcapsular cataract (PSC) is an opacity that
occurs at the rear end of the lens capsule. Ultrastructural
studies have suggested that the evolution of PSC is associated
with  fiber  swelling  and  breakdown,  which  in  turn  is
accompanied by the formation of a complex and peculiar
membrane structure [1].
In 1960, Black and colleagues first noted the relationship
between steroid usage and PSC [2]. It was also observed that
PSC developed only after a patient had been on a high dose
steroid treatment for longer than one year [3]. Moreover, the
development  of  PSC  has  been  observed  in  patients  with
diseases  such  as  rheumatoid  arthritis,  asthma,  as  well  as
kidney  transplant  recipients  who  have  continuously  taken
systemic  steroid  and  immunosuppressive  drug  treatment.
Topically  applied  steroids  and  inhaled  steroids,  taken  for
asthma, have also resulted in PSC [4]. This form of PSC as
well as cortical changes due to the administration of steroidal
drugs  occur  more  often  as  a  result  of  diffusion  of  such
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substances from the posterior chamber by crossing the blood-
aqueous barrier, uveal inflammation, and due to disturbance
of the vitreous humor [5]. The characteristic feature of steroid-
induced  PSC  is  that  it  shows  aberrant  migration  of  lens
epithelial cells, proliferation, and suppression of differences
in the lens [6].
Jobling and Augusteyn [4] suggested that administration
of steroids causes an alteration in the growth factors that are
reaching  the  lens.  These  alterations  in  the  expression  of
growth factors might be one of the causes for steroid-induced
cataract. Further, from other studies, it was understood that
these  growth  factors  are  responsible  for  the  induction  of
matrix metalloproteinases (MMPs) in the cells [7,8]. Reports
from several other in vitro and in vivo studies using animals,
human lens epithelial cells, and cell line culture have shown
that transforming growth factor-beta (TGF-β) and epidermal
growth factor (EGF) upregulate the expression of MMP-2 and
MMP-9 [9-13].
MMPs  represent  a  family  of  endopeptidases  that  are
capable  of  degrading  the  extracellular  matrix  (ECM)
molecules  and  thereby  maintaining  normal  physiologic
processes  such  as  morphogenesis  and  influencing  cell
biologic activities [14]. Wong and colleagues [15] have shown
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64that inhibition of MMPs prevents migration of lens epithelial
cells (LECs) and contraction of the lens capsule. It echoes a
similar function as that of steroids, which induce the aberrant
migration of lens epithelial cells. Similarly MMPs are also
found to enhance the migration of lens epithelial cells by an
undefined mechanism. It was also shown that multiple MMPs
are expressed in the lens and their expression is altered in
several cataract phenotypes [16].
In the eye, MMPs have been examined in several ocular
diseases  including  retinal  diseases,  glaucoma,  corneal
disorders,  scleritis,  uveitis,  pterygium,  and  cataract  [14,
17-19]. The most widely studied MMPs in the ocular tissues
are MMP-2 and MMP-9. In our previous study, we observed
that MMP-9 activity was higher in cortical cataract followed
by PSC and nuclear cataracts [20].
Since the role of MMPs in the genesis of PSC was not
understood, in the present study, we attempted to assess the
level  of  MMPs  especially  MMP-2  and  MMP-9  in  lens
epithelial cells as well as the serum of patients with PSC.
METHODS
Patient  selection:  This  prospective  observational  study
comprised  156  patients  with  uncomplicated  age-related
cataract  who  underwent  phacoemulsification  at  Iladevi
Cataract & IOL Research Centre Ahmedabad, India from
March,  2004  to  February,  2011.  Informed  consent  was
obtained from all patients. Only patients in the age group of
12–75  years  with  pupils  dilating  more  than  7.0  mm  and
with  otherwise  normal  eyes  were  included  in  the  study.
Inclusion criteria were eyes with PSC and steroid-induced
PSC.  Exclusion  criteria  were  eyes  with  diabetes  mellitus,
hypertension, glaucoma, shallow anterior chambers, uveitis,
high  myopia  (axial  length  <27.0  mm),  pseudoexfoliation,
traumatic  cataract,  subluxated  cataract,  previous  ocular
surgery, ocular disease, and allergy to dilating drops. The type
of cataract in all the patients was recorded according to the
zone of opacification. Under a slit lamp observation, the grade
of the cataract was recorded based on the degree of hardness
using the Emery and Little classification [21]. An experienced
surgeon (A.R.V.) performed all the surgeries under topical
anesthesia  using  a  standardized  technique  that  has  been
described  [22]  by  an  expert.  The  samples  are  distributed
according to experimental requirement as shown in Table 1.
Patients  medical  history:  A  detailed  medical  history  was
collected from the 50 steroid-induced PSC patients. The mean
age of the patients was 40.57±16.67 (12–68 years). To qualify
for this study, the patients had be on steroid therapy for at least
2 years. Of these the following patients were on oral steroid
therapy: 21 patients with renal transplantation, 8 with asthma,
2 with lung disease, 3 with arthritis, and 16 with allergy. The
following  steroids  were  administered:  Wysolone
(Prednisolone; Lupin Ltd, Mumbai, MH, India and Ranbaxy,
Gurgaon,  Haryana,  India),  Dexamethasone  (Taj
Pharmaceuticals  Ltd.  Mumbai,  MH,  India),  Omnipred
(Prednisolone  Acetate;  ALCON  chemical  Ltd,  Bangalore,
KA, India), Doxophyllin (Atman Pharmaceuticals, Mumbai,
MH, India), and Cyclosporin (Taj Pharma, Mumbai, MH,
India).  The  steroid-induced  PSC  patients  detailed
demographics shown in the Table 2. There were 106 patients
with non-steroid PSC. The mean age of these patients was
53.43±9.92 (25–75 years).
Sample  processing  and  protein  estimation:  Blood  was
collected from patients with steroid-induced PSC (n=33) and
non-steroid induced PSC (n=89) before the administration of
anesthesia. From these collected blood samples, serum was
separated by centrifugation at 10,000× g for 15 min at 4 °C.
The serum was stored immediately at 4 °C, until used.
The curvilinear capsulorhexis, approximately 5 mm in
diameter, was removed from the anterior region of the lens
capsule during phacoemulsification and stored immediately
at  −20  °C  until  used.  The  samples  were
homogenized individually at 4 °C by adding 350 µl of cold 0.1
M potassium phosphate buffer (pH 7.5). All the samples were
given an equal number of strokes during homogenization to
obtain uniformity. The homogenate was centrifuged (Hereaus
Centrifuge, Buckinghamshire, England, UK) at 10,000× g for
15 min at 4 °C, and the supernatant was stored immediately
at 4 °C. The quantity of total protein in all the samples was
estimated by the Lowry method [23] using BSA as a standard.
Protein concentration was expressed in terms of microgram
per microliter (µg/µl) of homogenate.
Succinylation of gelatin: Gelatin was purchased from Sigma-
Aldrich (St. Louis, MO) and succinylated using the procedure
described previously [24]. Gelatin was dissolved in 50 mM
Sodium Borate buffer with 10 mM CaCl2, pH 7.0 for MMP-2
and  50  mM  borate  buffer,  pH  8.5  for  MMP-9,  at  a
TABLE 1. SAMPLE DISTRIBUTION OF STEROID-INDUCED PSC AND NON-STEROID INDUCED PSC BY TECHNIQUE.
    Sample
Technique MMPs Steroid-Induced PSC Non-Steroid Induced PSC
Succinylated-gelatin assay MMP-2 & −9 33 89
RT–PCR MMP-2 & −9 06 06
Immunofluorescence MMP-2 05 05
  MMP-9 06 06
Total   50 106
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65concentration  of  20  mg/ml.  An  equal  amount  of  succinic
anhydride was then gradually added to the solution and the
pH of the reaction was maintained at 7.0 for MMP-2 and 8.5
for  MMP-9.  The  succinylated  gelatin  was  then  dialyzed
extensively against 50 mM sodium borate buffer, pH 7.0 and
8.5, respectively. Since dialysis resulted in dilution of the
gelatin,  the  final  concentration  was  determined  using  the
Lowry’s method [23].
Succinylated gelatin assay: Succinylated gelatin assay [25]
was used for the analysis of MMP-2 and MMP-9 activities.
Briefly,  about  50  μl  of  enzyme  source  and  200  μg  of
Succinylated gelatin was added and the final volume was
made up to 1.5 ml with 50 mM Sodium Borate buffer and with
10 mM CaCl2, pH 7.0 for MMP-2 and 50 mM borate buffer,
pH 8.5 for MMP-9. A blank without substrate but with borate
buffer and enzyme source was prepared for each enzyme
assay. The contents were incubated at 37 °C for 30 min. About
500 μl of 0.03% solution of 2,4,6-trinitro benzene sulfonic
acid (TNBSA; Sigma-Aldrich) was then added to the reaction
mixture  and  allowed  to  incubate  at  room  temperature  for
another 20 min. The optical density (OD) of each reaction was
obtained  at  450  nm  using  a  PerkinElmer  UV/VIS
spectrophotometer  (Molecular  Devices,  Menlo  Park,  CA).
The inhibitory capacity (%) was evaluated by comparing the
relative activity of the enzyme in the presence and absence of
the  MMP-2  inhibitor  I  and  MMP-9  inhibitor  I.  Enzyme
activity in the absence of the inhibitor was considered to be
100%. A standard graph was plotted using purified MMP-2
and MMP-9 (Sigma Aldrich) and was used for calculation of
MMP-2 and MMP-9 activities in all the samples. The MMP-2
and  MMP-9  activities  were  expressed  in  nanogram  per
microgram (ng/µg) of total proteins.
Real-time PCR quantification: Total RNA was extracted from
freshly  collected  capsulorhexis  samples  using  TRIZOL
(Invitrogen-Gibco,  Grand  Island,  NY)  according  to  the
manufacturer’s protocol. One microgram of total RNA was
reverse transcribed at 25 °C for 5 min, 42 °C for 60 min, and
70 °C for 5 min in 20 µl of 0.5 µg of oligo (dT), 20 pmol
primer, 3 mM of MgCl2, 1 mM of dNTPs, 4 µl of Improm-
IITM 5× reaction buffer (Promega, Madison, WI), 1 unit of
Recombinant RNasin® RNase Inhibitor and 1 µl of Improm-
II™ Reverse Transcriptase (Promega). For quantitative PCR,
amplifications were performed on a Roche LightCycler 480
(Roche Ltd., Berlin, Germany) in 20 µl of reaction using 2µl
of cDNA, 10µl of SYBR Green I Master, and gene specific
primers  at  the  mM  concentration.  The  amplification  was
performed at 95 °C for 5 min before the first cycle, 95 °C for
5 s, and 72 °C for 30 s repeated 50 times. Quantitative PCR
was  performed  for  MMP-2  and  MMP-9,  and
glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH)  was
used as the house-keeping gene. All the primers obtained from
SABiosciences (SABiosciences, New Delhi, India) are listed
in Table 3. The mRNA levels were expressed as ratios, using
the delta-delta method for comparing the relative expression
results between steroid-induced PSC and non-steroid induced
PSC. The non-parametric Mann–Whitney U test was applied
for statistical evaluation and p values <0.05 were considered
statistically significant.
Immunostaining: Antibodies for MMP-2 and MMP-9 were
obtained  from  Novus  Biologicals  (Littleton,  CO)  and
AnaSpec (Fremont, CA), respectively. Fluorescently tagged
TABLE 2. DETAILED STEROID-INDUCED PSC PATIENTS DEMOGRAPHICS.
Disease for which
steroids were
prescribed
Number of
patients Steroids used
Use of
Cyclosporin
Oral or topical
therapy
Time
period for
which the
steroid
therapy
lasted
Prescribed
dosage of
steroid
Time since
PSC
developed
Renal transplantation 21 WY/CY 5 mg/day Oral >2–4 years 5–10 mg/day Not recorded
Asthma 08 WY/DE/DP - Oral >2–4 years 10 mg/day Not recorded
Lung disease 02 WY/DE - Oral >2 years 7–10 mg/day Not recorded
Arthritis 03 OP/DP - Oral >2–3 years 10 mg/day Not recorded
Allergy 16 WY/DE/DP/OP - Oral/topical >2–3 years 10 mg/day Not recorded
           WY-  Wysolone  (Prednisolone);  DE-  Dexamethasone;  OP-  Omnipred  (Prednisolone  Acetate);  DP-  Doxophyllin  and  CY-
           Cyclosporin.
TABLE 3. DETAILS OF QRT–PCR PRIMERS OBTAINED FROM SABIOSCIENCES.
Number Gene
Catalog number of primers for
SA Biosciences Accession number
1 GAPDH PPH00150E NM_002046
2 MMP-2 PPH001510B NM_004530
3 MMP-9 PPH00152E NM_004994
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66secondary antibodies were obtained from Invitrogen. All other
chemicals were purchased from Sigma-Aldrich (St. Louis,
MO). Capsulorhexis specimens were placed on silane (amino-
propyl-triethoxy silane)-coated glass slides with LECs facing
the slide and fixed in 2% paraformaldehyde in phosphate-
buffered saline (PBS) for 5 min. The samples were rinsed with
PBS and chilled acetone-methanol (1:1) was used for further
fixation. The capsule of the specimen was peeled with the help
of forceps leaving LECs on the slides. These cells were used
for  immunolocalization  of  MMP-2  and  MMP-9.  Antigen
retrieval of MMP-9 was performed using Proteinase k (20 µg/
ml) for 1 min at 37 °C. Antigen retrieval of MMP-2 was
performed using 0.25% Triton-X 100 for 10 min. Following
blocking and standard washing procedures, the cells were
incubated with Rabbit anti-MMP-2 (1:100) and Mouse anti-
MMP-9 (1:100) antibodies for 1 h at 37 °C. The cells were
then washed with PBST (PBS containing 0.05% Tween-20),
and incubated with appropriate secondary antibodies tagged
with Alexa fluor 546 and Alexa fluor 488 (1:200 dilution;
Invitrogen,  Grand  Island,  NY).  4',  6-diamidino-2-
phenylindole (DAPI) was used to counter-stain the nuclei. An
epifluorescence microscope (Axioskope II; Carl Zeiss, New
York, NY) was used to observe the cells and the images were
documented with a CCD camera (Cohu, San Diego, CA).
Statistical analysis: Statistical comparisons were performed
using non-parametric tests such as the Kruskal–Wallis and
Mann–Whitney tests.
RESULTS
Of  the  156  patients  with  uncomplicated  cataract,  50  had
steroid-induced PSC (mean age 40.57±16.67 [SD]) and 106
had non-steroidal PSC (mean age 53.43±9.92 [SD]).
Table 4 shows the mean value of MMP-2 and MMP-9
activities in the LECs and serum of steroid-induced PSC and
non-steroidal  PSC.  The  difference  in  the  mean  activity
between  steroid-induced  PSC  and  non-steroidal  PSC  was
statistically significant (p<0.001). Steroid-induced PSC had
significantly higher activity of MMP-2 and MMP-9 in the
LECs and serum as compared with non-steroidal PSC.
Table  5  shows  the  results  of  the  post-hoc  statistical
analysis  for  multiple-paired  comparisons  of  the  mean
difference in MMP-2 and MMP-9 activities in LECs and
serum  of  steroid-  induced  and  non-steroidal  PSC.  A
statistically significant difference was seen between steroid-
induced and non-steroidal PSC (p<0.001), with the highest
TABLE 4. DESCRIPTIVE STATISTICS OF MMP-2 AND MMP-9 ACTIVITIES IN LECS AND SERUM OF STEROID-INDUCED PSC AND NON-STEROID
INDUCED PSC.
    Mean activity (ng/µg proteins±SD)
Cataract MMPs LECs Serum
Steroid-induced PSC (n=33) MMP-2 2.28±0.23 56.08±3.09
  MMP-9 5.96±0.20 735.97±85.35
Non-steroid PSC (n=89) MMP-2 1.62±0.13 47.29±2.31
  MMP-9 5.53±0.18 540.49±14.11
           MMP-2 and MMP-9 activities differ significantly between all the groups (p<0.001, ANOVA); SD, standard deviation; n- No.
           of Subjects, Steroid PSC- steroid-induced posterior subcapsular cataract; PSC-posterior subcapsular cataract.
TABLE 5. MULTIPLE COMPARISONS USING THE BONFERRONI TEST FOR POST-HOC ANALYSIS OF MMP-2 AND MMP-9 ACTIVITIES IN LECS AND SERUM OF
STEROID-INDUCED PSC AND NON-STEROID INDUCED PSC.
      Steroid PSC (n=33) PSC (n=89)
      LECs                                   Serum                                  LECs                                  Serum
Cataract Sample MMP −2 −9 −2 −9 −2 −9 −2 −9
Steroid PSC
(n=33)
LECs −2   <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
    −9 <0.001   <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
  Serum −2 <0.001 <0.001   <0.001 <0.001 <0.001 <0.001 <0.001
    −9 <0.001 <0.001 <0.001   <0.001 <0.001 <0.001 <0.001
Non steroid
PSC (n=89)
LECs −2 <0.001 <0.001 <0.001 <0.001   <0.001 <0.001 <0.001
    −9 <0.001 <0.001 <0.001 <0.001 <0.001   <0.001 <0.001
  Serum −2 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001   <0.001
    −9 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001  
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67activity of MMP-2 and MMP-9 in the LECs and serum of
steroid-induced  PSC.  The  post-hoc  analysis  therefore
supported the ANOVA.
Table 6 shows the ratio of MMP-2 activity in the LECs
and serum of steroid-induced and non-steroidal PSC. MMP-2
activity was increased by 0.4 and 0.18 fold in the LECs and
serum of steroid-induced PSC respectively. Further, this table
also shows the ratio of MMP-9 activity in the LECs and serum
of steroid-induced and non-steroidal PSC. MMP-9 activity
was increased by 0.4 and 0.07 fold in the LECs and serum of
steroid-induced PSC respectively. Table 7 compares the levels
of MMP-2 and MMP-9 activity in the LECs and serum of
steroid-induced PSC. The MMP-2 ratio between the LECs and
serum decreased in steroid-induced PSC (1:25) as compared
to  non-steroidal  PSC  (1:29).  However,  the  MMP-9  ratio
between the LECs and serum increased in steroid induced PSC
(1:124) as compared to non-steroidal PSC (1:98).
To validate the results obtained from the succinylated
gelatin assay, we have used two techniques, namely qRT–
PCR  and  immunolocation.  The  mRNA  expression  of
MMP-2 and MMP-9 was evaluated using qRT–PCR in the
LECs of steroid-induced PSC and non-steroidal PSC. The
relative quantification compared to the house-keeping gene
GAPDH  showed  a  significant  upregulation  in  mRNA
TABLE 6. RATIO OF MMP-2 AND MMP-9 ACTIVITIES IN LENS EPITHELIAL CELLS (LECS) AND SERUM OF NON-STEROID AND STEROID-
INDUCED POSTERIOR SUBCAPSULAR CATARACT (PSC).
   
Mean activity (ng/µg proteins)
 
Cataract MMPs Non-steroid PSC (n=89) Steroid PSC (n=33) Ratio
LECs MMP-2 1.62 2.28 1:1.4
  MMP-9 5.53 5.96 1:1.07
Serum MMP-2 47.29 56.08 1:1.18
  MMP-9 540.49 735.97 1:1.36
TABLE 7. RATIO OF MMP-2 AND MMP-9 ACTIVITIES IN LECS VERSES SERUM OF NON-STEROID AND STEROID INDUCED PSC.
MMPs
Non-steroid PSC
 (LECs: Serum)
  Steroid PSC
(LECs: Serum) Ratio
MMP-2 1:29.2 1:24.5 Down
MMP-9 1:97.7 1:123.5 Up
Figure  1.  Expression  of  MMP-2  and
MMP-9  mRNA  in  steroid  and  non-
steroid  induced  PSC.  The  graph
represents the quantitative analysis of
MMP-2 and MMP-9 mRNA expression
and  both  are  higher  in  the  LECs  of
steroid-induced  PSC  as  compared  to
non-steroid induced PSC.
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68expression of MMP-2 and MMP-9 in steroid-induced PSC
(Figure 1) compared to non-steroidal PSC with p-values of
0.001 and 0.04, respectively. Immunolocalization of MMP-2
and MMP-9 in the LECs of steroid-induced PSC and non-
steroidal PSC further validated the results of the succinylated
gelatin  assay.  MMP-2  was  observed  in  the  nucleus  and
cytoplasm  of  the  LECs  (Figure  2A,D)  and  MMP-9  was
observed in a punctuated form in the cytoplasm of the LECs
(Figure 3A,D). The MMP-2 and MMP-9 levels were higher
in the LECs of steroid-induced PSC (Figure 2D and Figure
3D).
DISCUSSION
The  development  of  steroid-induced  PSC  is  a  complex
mechanism  and  several  attempts  have  been  made  to
understand  its  genesis,  but  it  has  not  been  convincingly
explained.  However,  in  recent  years,  osmotic  imbalance,
oxidative damage, imbalance in ocular growth factors, and
subsequent changes in the cellular enzymatic levels have been
recognized as promising factors in the development of steroid-
induced PSC [4,6]. There is growing evidence that MMPs also
play an important role in many disease processes, but most of
these enzymes are likely to be active at a local tissue level
[26].  While  other  studies  have  reported  and  localized  the
presence of MMPs in normal as well as in cataractous lenses,
the role of MMPs in the genesis of cataract has not been
reported [27,28]. Several studies have suggested that growth
factors  [7-13]  and  estrogen,  a  steroidal  hormone,  are
responsible for the induction of MMPs in cells [29]. A few
studies have reported that oxidative stress [27] and growth
factors (TGF-β) induce MMP-2 and MMP-9 activities in lens
epithelial cells [11,12,30]. Oxidative stress has been shown to
upregulate transcription and MMP activity in several types of
cells, including hepatic stellate cells [31], human monocytes
[32], and human coronary smooth muscle cells [33]. Ye and
Azar [34] suggested that the penetration and migration of
several cell types through the extracellular matrix (ECM)
requires the activity of MMPs. Thus, it can be suggested that
the abnormal induction of MMPs due to the administration of
steroids or due to growth factors may result in the degradation
of extracellular matrix substances that in turn help in the
migration of undifferentiated anterior epithelial cells to the
posterior pole forming PSC.
In our previous study, we have quantified the level of
MMP-9 activity in different types of cataractous LECs, and
MMP-9 activity was found to be high in cortical cataract
Figure 2. Localization of MMP-2 in lens epithelial cells (LECs) of human senile cataracts. MMP-2 levels are higher in the cytoplasm of LECs
of steroid-induced PSC and MMP-2 expression was also observed in some of the cell nuclei. Non-steroid induced PSC; SPSC-steroid-induced
PSC; LECs-lens epithelial cells, scale bar; 55µm.
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69[20]. However, no special effort was made to associate the
levels of MMP-9 activity with the clinically observed steroid-
induced  PSC.  Hence  the  present  study  was  designed  to
measure the levels of MMP-2 and MMP-9 activities in the
LECs and serum of steroid-induced PSC. We have selected
serum as the second system, since we intended to analyze
whether the increased level of MMP-2 and MMP-9 activities
in the LECs was due to the normal physiologic status or due
to the administration of drugs.
In the present study, individual anterior capsular samples
(LECs) obtained by anterior capsulorhexis as well as serum
of the same patients were used. As LECs are known to have
low protein content, a sensitive method was required. It is well
known that the levels of expression and activity of MMPs can
also be determined by ELISA [35], flow cytometric analysis
[36], and mRNA (mRNA) expression analysis [28]. We used
succynylated  gelatin  assay,  qRT–PCR,  and
immunolocalization to analyze the expression of MMP-2 and
MMP-9 in steroid-induced and non-steroidal PSC. Baragi et
al. [25], while evaluating the succinylated gelatin assay, found
that this method relies upon the exposure of primary amines
after the substrate has been degraded by gelatinases and also
quantifies the specific activity. Further, the other advantages
of  this  assay  were  that  the  protocol  required  only  small
quantities of sample and it was found to be sensitive enough
to detect quantities as low as 0.1ng of MMP-2 and MMP-9.
In  the  present  study  and  from  observations  made  in  our
previous study, we found succinylated gelatin assay a suitable
and sensitive method for measuring MMP activity in LECs.
The  RT–PCR  results  in  the  present  study  showed  higher
expression of both MMPs in the LECs of steroid-induced
PSC.  Similarly  we  also  observed  higher
immunohistochemical localization of MMP-2 and MMP-9 in
the cytoplasm of steroid-induced LECs.
The results from the present study revealed an increase
in MMP-2 and MMP-9 activities in the LECs and serum of
steroid-induced PSC. The patients recruited in the present
study received steroids such as Dexamethasone, Wysolone
(Prednisolone),  Omnipred  (Prednisolone  Acetate),  and
Doxophyllin  (topical  as  well  as  oral)  as  well  as  the
immunosuppressive  drug  (Cyclosporin).  Although  several
studies  report  tantalizing  results  claiming  that  steroids
influence the modulation of MMP activity, a report by Choe
and coworkers [37] suggests that methylprednisolone causes
emphysema-like changes in the lungs of rats due to an increase
in MMP activity. Further, cyclosporine A, which is taken as
an immunosuppressive drug after kidney transplantation, was
also found to upregulate the expression of MMP-2 in rat hearts
[38]  and  both  MMP-2  and  MMP-9  in  cultured  human
trophoblast  cells  [39].  Another  study  by  Poulalhon  and
colleagues [40] reported that the immunosuppressive drug,
rapamycin, enhanced the expression of MMP-1. Thus, we
presume that the increased activity of MMP-2 and MMP-9 in
LECs may be due to the administration of such drugs.
In the case of PSC, the levels of MMP-2 activity between
the LECs and serum was in the ratio of 1:29, which was shown
to be reduced to 1:25 in the case of steroid-induced PSC. The
reduction in MMP-2 activity in the serum of steroid-induced
Figure 3. Localization of MMP-9 in lens epithelial cells (LECs) of human senile cataracts. The MMP-9 levels are higher in the cytoplasm of
LECs of steroid-induced PSC. PSC-non steroid induced PSC; SPSC-steroid induced PSC; LECs-lens epithelial cells, scale bar; 35µm.
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70PSC  may  be  attributed  to  the  administration  of  steroids.
However, the ratio of MMP-9 activity between the LECs and
serum of steroid-induced PSC was higher than non-steroidal
PSC. Since several studies have documented a rise in plasma
levels of MMP-9 in cancer, hepatic and lung diseases and
rheumatoid arthritis [41-44], subjects with a history of these
conditions were excluded from this study. The reason for the
observed increase in the level of circulating MMP-9 in the
serum of steroid-induced cataract could not be understood.
However, it could be attributed to the combined effect of
steroids  and  immunosuppressive  drugs.  Nevertheless,  the
cause of increased MMP-9 activity in steroid-induced PSC
remains unclear. It is possible that circulating leukocytes,
macrophages [45], vascular endothelial cells [46], fibroblasts
and  smooth  muscle  cells  [47,48]  may  contribute  to  the
increased  levels  of  MMP-9  activity.  The  absence  of  an
increase in MMP-2 levels in the serum may reflect its more
constitutive  expression,  whereas  MMP-9  levels  are  more
responsive to external factors such as reactive oxygen species
[49], inflammatory cytokines [49], immunosuppressive drugs
[38], and other steroids [37].
In  summary,  this  is  the  first  study  that  reveals  an
association between MMPs and steroid-induced PSC. MMP-2
and MMP-9 activities in the LECs and serum significantly
differed between steroid-induced PSC and non-steroidal PSC.
MMP-9 activity was higher in the serum of steroid-induced
PSC;  serum  can  be  used  as  a  secondary  source  to  detect
steroid-induced PSC. We realize that it is difficult to make
wide-ranging  conclusions/assumptions  based  on  these
observations in view of the small sample size used. However,
this is an important starting point. Larger scale future studies
will be required to clarify these findings including the link
between growth factors and systemic inflammatory markers.
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